Skip to main content
OpenTrials
Completed

NCT Number: NCT03567863

Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles

Multicenter randomized prospective study

Criteria for inclusion:

Patients admitted for EUS-FNB of a pancreatic mass

Goals of the study:

To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.

Main criterion:

- Biopsy core length of target tissue obtained by needle pass

Number of patients:

60 patients

Duration of the study:

1 year

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

David Karsenti

Charenton-le-Pont, Île-de-France Region, 94220, France

About this study

Type of study:

Multicenter randomized prospective study

Criteria for inclusion:

Patients admitted for ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY (EUS-FNB) of a pancreatic mass

Exclusion criteria

Patients with an extra-pancreatic mass puncture Echendoscopic puncture contraindication or vascular interposition

Goals of the study:

To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.

Evaluation criteria :

Main criterion:

  • Biopsy core length of target tissue obtained by needle pass

Secondary criteria

  • Presence of a core biopsy specimen
  • Sensitivity of EUS-FNB for the diagnosis of adenocarcinoma of the pancreas
  • False negative rate, Negative predictive value for the diagnosis of pancreatic adenocarcinoma
  • Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface on All core biopsy specimens
  • Success rate of isolation of tumor cells and determination of transcriptomic signatures of pancreatic adenocarcinoma subtypes
  • Immediate complications of puncture
  • Variation in the quality of the puncture following the trans-duodenal or trans-gastric access route
  • Technical failure rate of puncture
  • Optional: inter and intra-observer evaluation of the anatomopathological criteria used (presence of a biopsy core, length of target tissue core per needle passage)

Number of patients:

60 patients

Duration of the study:

1 year

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient admitted to one of the investigative centers for endoscopic pancreatic puncture during the period from April 1, 2018 to April 1, 2019
  • Patient whose age is greater than or equal to 18 years and less than 90 years
  • Patient ASA 1, ASA 2, ASA 3 (ASA: American Society of Anaesthesiologists Classification)
  • Lack of participation in another clinical study
  • Signed informed consent

Exclusion criteria

  • Patients punctured with an extra-pancreatic mass
  • Patient under the age of 18 or over 90
  • Patient ASA 4, ASA 5
  • Pregnant woman
  • Patient with coagulation abnormalities preventing puncture: TP <50%, Platelets <50000 / mm3, effective anticoagulation in progress, clopidogrel in progress
  • Vascular or ductal or surgical fixation (Billroth II, Roux in Y) preventing endoscopic access to the lesion to be punctured
  • Patient unable to personally consent

Treatment and study plan

20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®

Device

The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)

22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®

Device

The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)

Primary outcomes

  1. cumulative length of tissue core biopsies per needle pass

    Time frame: in the 7 days after procedure

    cumulative length of tissue core biopsies per needle pass in mm

Secondary outcomes

  1. Presence of core biopsy specimen

    Time frame: in the 7 days after procedure

    Presence of core biopsy specimen

  2. Sensitivity

    Time frame: in the 7 days or 6 months

    EUS-FNB Sensitivity for the diagnosis of adenocarcinoma of the pancreas

  3. Specificity

    Time frame: in the 7 days or 6 months

    EUS-FNB Specificity for the diagnosis of adenocarcinoma of the pancreas

  4. Positive Predictive Value

    Time frame: in the 7 days or 6 months

    EUS-FNB Positive predictive value for the diagnosis of adenocarcinoma of the pancreas

  5. Negative Predictive Value

    Time frame: in the 7 days or 6 months

    EUS-FNB Negative Predictive Value for the diagnosis of adenocarcinoma of the pancreas

  6. Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface

    Time frame: 6 months

    Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface on All Core biopsies

  7. Success rate of isolation of tumor cells

    Time frame: 6 months

    Success rate of isolation of tumor cells

  8. Morbidity

    Time frame: 7 days

    Puncture Morbidity (acute pancreatitis, haemorrhage)

  9. Feasibility

    Time frame: during procedure

    Technical failure rate of puncture because of a impossibility to access to pancreatic mass with the needle (due to the needle stiffness)

  10. inter evaluation of the anatomopathological criteria used (presence of a biopsy core, length of target tissue core per needle pass)

    Time frame: 7 days

    inter evaluation of the anatomopathological criteria used (presence of a biopsy core, length of target tissue core per needle pass)

  11. determination of transcriptomic signatures of pancreatic adenocarcinoma subtypes

    Time frame: 6 months

    determination of transcriptomic signatures of pancreatic adenocarcinoma subtypes

  12. intra-observer evaluation of the anatomopathological criteria used

    Time frame: 7 days

    intra-observer evaluation of the anatomopathological criteria used

Sponsors and collaborators

Lead sponsor

Société Française d'Endoscopie Digestive

Other

Registry information

Official study title

Multicentric Randomized Study Comparing the Histological and Molecular Material Quality Obtained by EUS-FNB of Pancreatic Mass With Two "Biopsic" Needles: the 20-gauge Procore® (Cook) and the 22-gauge Acquire® (Boston Scientific)

Acronym: HISTOPAN

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 26, 2018
Registry last updated
Oct 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.